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Abstract
Background: Substance abuse has been considered as a growing challenge in Georgia that is closely linked with
human immune deficiency virus (HIV) and hepatitis C transmission due to unsafe injection and other uncontrolled
behaviors. Methadone maintenance therapy is one of the major treatment options for opioid-dependent
individuals. It has proven efficacy in decreasing illegal opioid consumption and criminal behavior as well as
reducing the level of HIV infection, mortality, HCV infection, and increasing social functioning.
Methods: The data was initially extracted from the electronic database, as of October 30, 2015, for the patients
undergoing methadone maintenance therapy in 2014 and 2015. We used two types of statistical analysis: binary
regression and time-to-event analysis (Kaplan-Meier). For binary regression analysis, patients who initiated the
treatment 12, 9, 6, and 3 months prior to October 30, 2015, respectively, were eligible for >12-, >9-, >6-, and
>3-month retention analysis. We identified two types of the retention periods: (I) “the program specific retention
period” (the time spent (uninterruptedly) in the Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria (GFATM)
opioid substitution treatment (OST) program after the clients’ last entry) and (II) “being on OST retention period”
(the time spent (uninterruptedly) on OST since the clients’ last entry).
For time-to-event analysis, the two different endpoints were investigated: (i) dropouts and (ii) being detained.
Results: The analysis showed that at each time point, “being on OST retention” rates are slightly higher than
“program specific retention” rates. The percentages of patients retained in OST treatment after 3, 6, 9, and
12 months from the initiation of the treatment, respectively, were 89, 86, 85, and 83% and the percentages of
patients retained in the GFATM program at the same time points were 88, 83, 82, and 80%. Patients older than
40 years are twice as likely to stay in the program compared to younger individuals. Gender is only associated with
>9 and >12 months retention with approximately three times the odds for men compared to women. The strength
of the association between hepatitis C status and “program specific” retention increases with time spent in the
program as p values decrease from 0.07 for >3- and >6-month retention to 0.01 for >9- and >12-month retention.
The younger age group was more likely to get dropouts and be detained. HIV status and social status did not show
statistically significant association with retention.
Conclusions: These findings identify the need for more support for younger patients as they are more vulnerable
to dropouts and detention compared to the older age group, especially during the early stage of treatment.
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Background
Substance abuse has been considered a growing challenge
in Georgia that is closely linked with human immune defi-
ciency virus (HIV) and hepatitis C transmission due to
unsafe injection and other uncontrolled behaviors.
According to studies conducted in 2009, 2012, and 2015,
the number of people who inject drugs has increased from
40,000 to 45,000 and then to 49,700 [1–3].
The estimated HIV prevalence in Georgia is 0.3%
(0.2–0.4%) among the adult population (15–49 years of
age). Injecting drug use was considered the leading route
of HIV transmission in the early stages of the HIV epi-
demic in Georgia. Since 2012, however, heterosexual
intercourse has become the major route of transmission
(44% in 2012, 49% in 2013, and 45% in 2014) [4].
According to the Infectious Disease, AIDS and Clinical
Immunology Center, HIV infection acquired through
injecting drug use accounts for 45.9% of cases [5].
Worldwide, there are 12 million people who inject
drugs (PWID), of whom 14.0% are living with HIV [6].
The comparative analysis of Bio-Behavioral Surveil-
lance Survey (BBS) results conducted in the last 5 years
(2009–2014) showed significant changes in the injecting
drug scene [2, 7, 8]. Heroin is the most commonly mis-
used substance among drug users in Georgia. Use of
heroin dropped in 2012 by 23.3% compared to 2009 and
increased again in 2015 reaching 58.1%. Changes in
buprenorphine (the second most frequently injected
drug) misuse had a similar pattern to heroin; it dropped
from 43.3% in 2009 to 13.4% and then increased in 2015
to 25.9%. Self-made desomorphine, containing the sub-
stance known as “Krokodile,” was first captured by BBS
studies in 2012. This drug is a cheaper alternative to
heroin and shows high potential to cause dependence
and injecting-related harm. However, in 2015, self-made
injecting drug use, including desomorphine, was
reported by a lower proportion of PWIDs compared to
2012.
In 2014, the opiates affected some 17 million people in
the world. The decline of opium production in 2015 is un-
likely to lead to shortages in the global heroin market given
the high opium production levels of previous years [6].
Methadone maintenance therapy is one of the major
treatment options for opioid-dependent individuals. It
has proven efficacy in decreasing illegal opioid consump-
tion and criminal behavior as well as reducing the level
of HIV infection, mortality, hepatitis C virus (HCV)
infection, and social functioning. There are studies
reporting a positive impact of retention in opioid substi-
tution treatment (OST) on HIV outcomes: the longer
the duration of retention in OST, the higher the likeli-
hood of long-term virological success [9, 10].
OST was introduced in Georgia in 2005. Nowadays,
OST is functional through three sources: (I) the donor:
The Global Fund to Fight HIV/AIDS, Tuberculosis, and
Malaria (GFATM), (II) the state program, and (III) the
private sector. There are two different OST programs
available: (1) methadone maintenance program and (2)
the program using combined preparation with buprenor-
phine and naloxone.
The state program is based on the co-payment
principle: the cost of the methadone is covered by the
State, while services (visit to doctor, counseling, urine-
testing, etc.) are self-paid (out-of-pocket) by patients at
GEL 110 a month. The co-payment does not apply to
HIV-positive individuals and those under the poverty
line. In total, there are 15 sites operated by the State
throughout the country. In 2015, the country’s total
capacity for OST was 2750 (the state program had 2000
patients and the GFATM 750 patients) patients.
The National Center for Disease Control and Public
Health (NCDC) of Georgia through the GFATM-funded
HIV prevention program provides treatment at six OST
sites. There are four sites in Tbilisi (the capital city), one
in Gori (east Georgia), and one in Batumi (southwest
Georgia). Additionally, two sites are running in the peni-
tentiary institutions—one in Tbilisi and another in
Kutaisi (west Georgia), providing long-term detoxifica-
tion of methadone. Figure 1 represents the country’s
OST total coverage.
We conducted the operational study to investigate
retention in OST and associated factors.
Methods
GFATM OST program uses an electronic web-based
real-time data collection tool in which the data is en-
tered on a daily basis.
The clients’ information which are routinely collected
are (1) client’s ID, (2) residency address, (3) date of birth,
(4) gender, (5) date of program entry, (6) date of pro-
gram cessation, (7) reason of cessation, (8) OST program
provider name and address, (9) hepatitis C status, (10)
acquired immune deficiency syndrome (AIDS) status,
and (11) social status.
The data was initially extracted from the electronic
database as of October 30, 2015, for the patients under-
going methadone maintenance therapy in 2014 and
2015. All duplicates as well as observations for which
the program entry date was missing were excluded. The
final data set included 1051 individuals out of an initial
1249.
Definitions
The database consisted of patients (i) transferred from
other OST programs into the GFATM OST program
and (ii) those originally entered in the GFATM OST
program. For this reason, we identified two types of the
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retention periods: (I) “the program specific retention
period” and (II) “being on OST retention period.”
1. “The program specific retention period” was defined
as the time spent (uninterruptedly) in the GFATM
OST program after the clients’ last entry.
2. “Being on OST retention period” was defined as the
time spent (uninterruptedly) in OST since the
clients’ last entry.
For those patients which only had GF OST program
experience “the program specific retention period”
and “being on OST retention period” coincided with
each other.
3. “Dropout” was defined as a failure to adhere to the
regimen (e.g., frequent use of additional narcotics or
alcohol, missed sessions more than ten times,
incorrect code of conduct towards the staff, attempt
of drug stealing or drug dealing at the service area)
or abandoning the program with or without
notification.
Binary regression analysis
Patients who initiated the treatment 12, 9, 6, and
3 months prior to October 30 were, respectively, eligible
for >12-, >9-, >6-, and >3-month retention analysis
(Fig. 2).
The outcome variable (retention) at different time
points was calculated as follows: (I) more than 3-month
retention ≥90 days stay, (II) more than 6-month reten-
tion ≥181 days stay, (III) more than 9-month retention
≥270 days stay, and (IV) more than 12-month retention
≥365 days stay (Fig. 3).
The independent variables were age at program entry
(grouped at median value ≤40 and >40 years old and as
a continuous variable), hepatitis C status, HIV status,
gender, and being socially vulnerable. The latter was
Fig. 1 OST coverage—Georgia; Regions with OST centers; Other regions
Fig. 2 Clients’ eligibility chart for >3, >6, >9, and >12-month retention analysis
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defined as a patient who applied to the Social Service
Agency (SSA) in order to receive social assistance. The
database automatically captures the information about
the obtained social scores of the patient (at the moment
of the patient’s registration), if this patient has applied
for the social assistance and therefore is registered into
the SSA database.
First, univariate analyses were performed to assess the
strength of the association between each independent
variable and the outcome. Other variables were then
included in an initial multivariable model if they had a
univariate p value of <0.05 and showed statistically
significant association with the outcome as well as with
other exposure variables. In the final model, variables
were selected based on a significance threshold of p <
0.05. Separate multivariable modes were built for “pro-
gram specific” and “OST specific” retention periods.
Results are presented as estimated odds ratios (OR) with
corresponding 95% confidence intervals (CI) and p values.
All p values are two-sided and reported to three decimal
places with those less than 0.001 reported as p < 0.001.
Time-to-event analysis
Factors that showed statistically significant association
with retention in OST were further studied in relation to
two different endpoints (failure events): (I) dropouts and
(II) being detained, by contracting Kaplan-Meier survival
curves. Patient’s death or retention in the program until
the end of the study period as well as residential address
or clinic change was treated as censored data.
Due to the huge inequality in gender distribution
within the cohort (29 females vs. 1022 males), we did
not put gender as an exposure variable for time-to-event
analysis.
Analyses were performed using STATA version 11.
Results
Retention
Table 1 represents characteristics of all individuals in the
data set. Age ranged from 21 to 67 years with the mean
age of 40.4 years. Of the cohort, 97.2% were male, 4.19%
were HIV-positive, 48.8% were hepatitis C virus-positive,
21.5% were socially vulnerable, and 27.7% transferred
into the GFATM OST program from other OST
programs.
The analysis showed that at each time point, “being on
OST retention” rates are slightly higher than “program
specific retention” rates. The percentages of patients
retained in OST treatment after 3 months, 6, 9, and
12 months from the initiation of the treatment, respect-
ively, were 89, 86, 85, and 83% and the percentages of
patients retained in the GFATM program at the same
time points were 88, 83, 82, and 80%.
In univariate analysis, age showed a strong statistical
association with both “program specific” and “being on
OST specific” retention periods. Generally, at each time
point, patients older than 40 years have almost two
times the odds of staying in the program compared to
younger individuals. Per each year increase in age, the
odds of retention increases ~7%. Gender was associated
with only >9- and >12-month retention with about three
times the odds for men compared to women. Positive
hepatitis C status was only associated with “program
specific” retention periods at >9-month (1.73 95% CI
(1.15–2.63) and >12-month (1.76 95% CI (1.15–2.67)
time points. HIV status and social status did not show a
statistically significant association with retention
(Table 2).
In multivariable analysis, age remained as a strong pre-
dictor for retention. After adjusting for gender and hepa-
titis C status, the odds of patents’ retention increased by
~6% per each year increase of age. Hepatitis C status
and gender, after adjusting for age (as a group variable),
showed some statistically significant association with
retention (Table 3).
Cessation
From the total cohort, 32% (341) left the program, 2.3%
died (10), 14.1% (48) was detained, 19% (65) left the pro-
gram after the detoxification (in this case, this is the
planned gradual reduction of methadone doses), 35%
(120) ceased the treatment voluntarily (with or without
any notification or due to failure to keep the regimen),
16.4% (56) changed to another clinic, and 12.3% (42)
changed the residential address. For each reason of cessa-
tion, younger age group patients (<40) were proportionally
Fig. 3 The sample composition for each time point
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more compared to older age group patients, at p = 0.014
significant level.
For the patients who left the OST program, the me-
dian duration of stay in the OST program was 140 days
(interquartile (IQR) 31–558). The longest median
duration of stay (335 days IQR, 122–745 days]) was
observed among patients who left the program after the
detoxification course, followed by detainees with
140 days (IQR, 60–574) and dropouts with 56 days
(IQR, 23–190).
There was a significant difference in dropout and
detention times between the age groups (log rank tests for
both outcomes: p < 0.001). For the younger age group pa-
tients, the probability of experiencing the dropouts some
time after the end of the observation period was about
0.73 (95% CI 0.66–0.81), and for the old age group, it was
0.88 (95% CI 0.84–0.91). The younger age group was also
less likely to be detained sometime after the observation
period compared to the old age group (0.67 (95% CI 0.36–
0.86) vs. 0.95 (95% CI 0.93–0.98)) (Figs. 4 and 5).
Kaplan-Meier dropout probability estimates at the end of
the observation period were about 0.90 (95% CI 0.83–0.94)
for the transferred patients and 0.79 (95% CI 0.74–0.83) for
not transferred patients (log rank test p < 0.001). There was
no statistically significant difference in Kaplan-Meier deten-
tion probability estimates (0.80(95% CI 0.53–0.92) vs. 0.92
(95% CI (0.78–0.96), transferred vs. not transferred, log
rank test p = 0.059) (Fig. 6).
The occurrences of the endpoints between the
groups of hepatitis C-positive and -negative patients
were not statistically significant (log rank test for
dropouts p = 0.705 and for detention p = 0.148).
Discussion
Key results
Our analysis showed that age is a strong predictor for
retention. The odds of retention in OST enhance per
each year increase of age by 6%. In addition, patients
over 40 years of age retain longer and are less likely to
dropout or to be detained. Positive hepatitis C status is
associated with relatively longer retention periods (>9
and >12 months). Patients who came from the paid
program to the free-of-charge program have a higher
probability of experiencing dropouts or being detained
at some point after the end of the observation period.
Strengths and limitations
The strength of the study is that the data was extracted
from a real-time web-based electronic system which
captures and registers the basic characteristics of the
patients. The accuracy of the data is monitored on a
quarterly basis.
The results of association between gender and reten-
tion were not conclusive as females represent only 2.8%
of the cohort (29/1051).
Comparability with other studies
Due to different settings and definitions used in other
studies, the comparability of our findings is also limited.
Our study presents relatively high retention rates on
OST >80% even after 12 months of treatment, compared
to other studies’ findings. In a Ukrainian study, retention
rate was 67% at 12 months of treatment [11]. Our find-
ings are also highly compared to the WHO collaborative
study that included low-, middle-, and high-income
Table 1 Characteristics of the cohort (n = 1051)
% of patients n/N of patients Median; IQR [25–75%]
Age 40 [34–46]
Age group 1 (≤40) 49% 515/1051




Socially vulnerable 21.5% 226/1051
Hepatitis C status (confirmed cases) 48.8% 513/1051
HIV status 4.19% 44/1051
Came from other OST program/transfers 27.7% 291/1051
Retention in GF program (months) 8.0; IQR [2.9–31.5]
Retention in OST (months) 13.3; IQR [4.2–37.7]
>3-month retention 80.3% 844/1051
>6-month retention 67.5% 710/1051
>9-month retention 60.1% 632/1051
>12-month retention 52.9% 556/1051
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Table 2 Results of univariate analysis of association between the exposure variables and retention at different time points (the first row
represents the results for program specific data and the second row for “being on OST” data)
>3-month retention >6-month retention
OR (95% CI) p value OR (95% CI) p value
Age (>40 vs. ≤40 years) 2.47 (1.62–3.77) <0.001 1.89 (1.27–2.81) 0.002
2.38 (1.54–3.67) <0.001 2.04 (1.37–3.04) <0.001
Age (cont. variable) 1.07 (1.04–1.10) <0.001 1.06 (1.03–1.08) <0.001
1.07 (1.04–1.10) <0.001 1.06 (1.03–1.08) <0.001
Gender (male vs. female) 0.98 (0.29–3.33) 0.974 1.57 (0.56–4.43) 0.385
1.14 (0.34–3.89) 0.830 1.86 (0.67–5. 24) 0.224
Socially vulnerable 1.20 (0.73–1.97) 0.463 1.35 (0.83–2.21) 0.232
1.18 (0.71–1.98) 0.519 1.21 (0.75–1.96) 0.433
Hepatitis C status 1.45 (0.97–2.17) 0.071 1.43 (0.97–2.11) 0.072
1.25 (0.83–1.90) 0.281 1.02 (0.69–1.51) 0.908
HIV status 0.82 (0.31–2.18) 0.702 0.78 (0.33–1.85) 0.583
0.73 (0.28–1.93) 0.528 0.61(0.26–1.44) 0.265
>9-month retention >12-month retention
Age (>40 vs. ≤40 years) 2.23 (1.46–3.41) <0.001 2.49 (1.62–3.83) <0.001
2.41(1.59–3.66) <0.001 2.44 (1.59–3.73) <0.001
Age (cont. variable) 1.07 (1.04–1.10) <0.001 1.07 (1.04–1.10) <0.001
1.07 (1.05–1.10) <0.001 1.08 (1.05–1.11) <0.001
Gender 3.21 (1.28–8.07) 0.013 2.46 (0.95–6.41) 0.065
3.69 (1.49–9.14) 0.005 2.89 (1.13–7.43) 0.027
Socially vulnerable 1.19 (0.72–1.98) 0.487 1.14 (0.69–1.86) 0.612
1.17 (0.71–1.92) 0.534 1.18 (0.72–1.93) 0.515
Hepatitis C status 1.73 (1.15–2.63) 0.009 1.76 (1.15–2.67) 0.009
1.18 (0.79–1.78) 0.403 1.23 (0.82–1.86) 0.318
HIV status 0.77 (0.32–1.82) 0.550 1.14 (0.42–3.07) 0.797
0.61 (0.26–1.45) 0.265 0.89 (0.33–2.39 ) 0.816
Age (cont. variable) analysis “age” as a continious variable i.e. examains the retention per each year increase in age
Table 3 Multivariate analysis at >9- and >12-month time points (gender and hep C status are adjusted for age as a group variable)
Model I: program specific Model II: being on OST
OR 95% CI P values ORs 95% CI p values
9 months
Age (>40 vs. ≤40 years) 2.05 (1.34–3.15) <0.001 2.33 (1.53–3.55) <0.001
Age (cont. variable) 1.06 (1.03–1.08) <0.001 1.06 (1.05–1.09) <0.001
Gender (male vs. female) 2.71 (1.06–6.95) 0.038 3.18 (1.26–8.0) 0.014
Hepatitis C status 1.55 (1.01–2.37) 0.042
12 months
Age (>40 vs. ≤40 years) 2.36 (1.53–3.64) <0.001 2.37 (1.55–3.64) <0.001
Age (cont. variable) 1.06 (1.04–1.09) <0.001 1.06 (1.04–1.10) <0.001
Gender (male vs. female) 2.48 (0.95–6.48) 0.064
Hepatitis C status 1.58 (1.03–2.44) 0.034
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countries (averaging approximately 70% at 6 months)
[12]. Hans-Ulrich Wittchen et al. found that the reten-
tion rate in Germany at 12 months was 75% [13]. Six-
month treatment retention rates observed in our study
were similar to those found by Ukrainian researchers
[14, 15]. Such differences could be explained by the
different methodology used in different studies. When
we did a cross-sectional analysis of the retention rates
our findings were closer to what was observed in other
studies (Table 1) [11–13]. However, after excluding those
not eligible for the >3-, >6-, >9-, and >12-month reten-
tion, the rates become high.
Age, gender, and hepatitis C status were not associated
with retention at 6 or 12 months in a Ukrainian study
[11]. Soyka M. et al. found that younger age associates
with premature dropouts from the OST [16].
Being transferred from the paid program to the free-
of-charge program shows a positive association with
retention. These findings are consistent with Australian
study findings, conducted in 2013, which suggest that
dispensing fees have a negative impact on OST retention
as well as lifestyle and treatment. They also suggest that
sponsorship “… would potentially increase the retention
rate of income-poor OST program participants” [17].
Fig. 4 Kaplan-Meier survival curve for length of time since inclusion in OST until occurrence of dropouts; age ≤40; age
>40; p < 0.001
Fig. 5 Kaplan-Meier survival curve for length of time since inclusion in OST until occurrence of detention; age ≤40; age
>40; p < 0.001
Ruadze and Todadze Harm Reduction Journal  (2016) 13:35 Page 7 of 9
In Georgia, individuals can apply for the social benefit
at the SSA. The authorized person of the SSA (the social
agent) visits the family. During the visit, a “family declar-
ation” is filled in about the social-economic state of the
family on the basis of the information delivered by the
authorized person of the family. After allocation of the
information provided in the declaration in the unified
database and processing by established methodology, a
rating score is assigned to the family, which amount de-
fines the right of the family on any benefit (pecuniary so-
cial assistance, medical insurance, etc.) [18]. Individuals
who score below 70,000 are eligible for free-of-charge
state OST program [19]. However, for this analysis, all
individuals who applied for social status were classified
as socially vulnerable regardless of their obtained scores.
We took this approach since everyone who applies for
the social benefit considers themselves to be poor
enough to be eligible for the support. In our cohort, the
median score obtained from the SSA was 77,610 [IQR,
45,330–115,750] and mean value was 93,402.
Being socially vulnerable does not appear to be the
driving force for transferring; as in our cohort, socially
vulnerable people are equally distributed among those
transferred and not transferred from the paid OST
program. Among those who came from the other OST
program, 77% were not socially vulnerable. Their trans-
fer might indicate that, despite their social status, people
find it difficult to pay the OST fee. Our findings might
also suggest that being transferred from the paid pro-
gram to the unpaid program could be a motivator for
better retention rates. As it is noted in the World Drug
Report, 2016: “higher social-economic groups have a
greater propensity to initiate drug use than lower social-
economic groups, but it is the lower social-economic
groups that pay the higher price as they are more likely
to become drug dependents” [6].
Conclusions
These findings identify the need for more support for
younger patients as they are more vulnerable to drop-
outs and detention compared to the older age group,
especially at the early stage of treatment. More analysis
enabling a direct comparison between paid and free-of-
charge programs is needed to assess the retention and
associated factors.
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